Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachna T Shroff

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Journal of Hematology & Oncology|May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinomaReham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.
Cancer|November 19, 2016
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 studyPat Gulhati, Kanwal Raghav, Rachna T Shroff, et al.
BMC Cancer|July 16, 2010
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studiesMilind M Javle, Rachna T Shroff, Henry Xiong, et al.
Cancer|August 7, 2016
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistanceDaniel H Ahn, Milind Javle, Chul W Ahn, et al.
British Journal of Cancer|April 26, 2017
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2022
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based ChemotherapySunyoung Lee, Rachna T Shroff, Shalini Makawita, et al.
NPJ Precision Oncology|July 17, 2025
Multi-omic characterization of early-onset esophagogastric cancerLawrence W Wu, Sachin Kumar Deshmukh, Sharon Wu, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imagingJane E Rogers, Jonathan D Mizrahi, Graciela M Nogueras Gonzalez, et al.
Hepatology (Baltimore, Md.)|September 12, 2021
The immunogenomic landscape of resected intrahepatic cholangiocarcinomaFernando Carapeto, Behnaz Bozorgui, Rachna T Shroff, et al.
JCO Precision Oncology|July 28, 2018
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> MutationRachna T Shroff, Andrew Hendifar, Robert R McWilliams, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Journal of Hematology & Oncology|May 31, 2018
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinomaReham Abdel-Wahab, Gauri R Varadhachary, Priya R Bhosale, et al.
Cancer|November 19, 2016
Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 studyPat Gulhati, Kanwal Raghav, Rachna T Shroff, et al.
BMC Cancer|July 16, 2010
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studiesMilind M Javle, Rachna T Shroff, Henry Xiong, et al.
Cancer|August 7, 2016
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistanceDaniel H Ahn, Milind Javle, Chul W Ahn, et al.
British Journal of Cancer|April 26, 2017
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2022
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based ChemotherapySunyoung Lee, Rachna T Shroff, Shalini Makawita, et al.
NPJ Precision Oncology|July 17, 2025
Multi-omic characterization of early-onset esophagogastric cancerLawrence W Wu, Sachin Kumar Deshmukh, Sharon Wu, et al.
Journal of Gastrointestinal Oncology|November 18, 2021
Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imagingJane E Rogers, Jonathan D Mizrahi, Graciela M Nogueras Gonzalez, et al.
Hepatology (Baltimore, Md.)|September 12, 2021
The immunogenomic landscape of resected intrahepatic cholangiocarcinomaFernando Carapeto, Behnaz Bozorgui, Rachna T Shroff, et al.
JCO Precision Oncology|July 28, 2018
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> MutationRachna T Shroff, Andrew Hendifar, Robert R McWilliams, et al.
Pageof 8